Evaluation of risk of falls and orthostatic hypotension in older, long-term topical beta-blocker users by Ramdas, W.D. (Wishal) et al.
GLAUCOMA
Evaluation of risk of falls and orthostatic hypotension
in older, long-term topical beta-blocker users
Wishal D. Ramdas & Nathalie van der Velde &
Tischa J. M. van der Cammen & Roger C. W. Wolfs
Received: 20 May 2008 /Revised: 14 January 2009 /Accepted: 13 April 2009 /Published online: 19 May 2009
# The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract
Background Falls are a serious problem in the elderly, and
have recently been described as cardiovascular-mediated
side effects of beta-blocker eye drops. Therefore, we
investigated the possible association between the long-
term use of beta-blockers, prostaglandins and their combi-
nations in eye drops, and falls, dizziness and orthostatic
hypotension in older patients.
Methods All participants were long-term users of eye drops
containing beta-blockers, prostaglandins or their combina-
tions. They underwent a structured falls interview and
blood pressure measurement for testing of orthostatic
hypotension. The odds ratio for presence of orthostatic
hypotension or a positive falls history according to use of
beta-blocker eye drops was calculated with a binary logistic
regression analysis. The main outcome measures were a
positive falls history and the presence of orthostatic
hypotension.
Results In total, 148 of 286 subjects participated. After
adjustment for age, gender, and use of fall-risk-increasing
drugs other than beta-blocker eye drops, we found no
significant difference in fall risk [odds ratio (OR): 0.60;
95% confidence interval (CI): 0.268–1.327] between
patients using ophthalmic beta-blockers or a combination
of ophthalmic beta-blockers and prostaglandins, and
patients using ophthalmic prostaglandins only. Although
prevalence of orthostatic hypotension was higher in the
beta-blocker group (OR: 1.67; 95% CI: 0.731–3.793)
compared to the prostaglandin group, this was a non-
significant difference.
Conclusions In our study, we did not find a significant
association between long-term use of beta-blockers eye
drops and falls, dizziness or orthostatic hypotension in
older ophthalmic outpatients, compared to long-term use of
prostaglandin eye drops.
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Introduction
Many ophthalmic diseases are more common in the ageing
eye. One of them is glaucoma, for which current treatment
is based on lowering intraocular pressure (IOP) [1, 2].
Nowadays there is a wide range of topical medication
available. One of the older, but still frequently prescribed
topical drugs is timolol, which is a non-selective beta-
adrenoceptor antagonist without intrinsic sympathicomi-
metic activity. Blockading of beta-receptors leads to a
decrease of aqueous formation and lowering of the IOP [3].
With respect to cardiovascular and pulmonary systemic
side-effects, many reports have been published in the
literature. In a study in which the dose and effect of oral
and topical beta-blockers were compared, the systemic
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(side-)effects of topical timolol were the same as those
associated with oral timolol [4].
For newer drugs, such as the prostaglandin analogs, and
for carbonic anhydrase inhibitors, no cardiovascular side-
effects are known [5–7]. Therefore, nowadays many
ophthalmologists are considering exclusion of the (cheap
and effective) beta-blocker as a first-line drug in the
treatment of glaucoma, in favor of the new (and more
expensive) prostaglandin analogs.
Recently, falls induced by beta-blocker eye drops have
been described as cardiovascular-mediated adverse drug
reactions [8]. Falls are a serious problem in the elderly, and
are associated with increased morbidity and mortality. They
can lead to reduced functioning and early admissions to
nursing homes and long-term care facilities, but also to a
reduced quality of life [9]. Polypharmacy and the use of
certain (groups of) drugs have been found to be associated
with an increased risk of falling [10–12]. Withdrawal of
these drugs can result in a reduction of fall risk [13, 14].
Several case reports have described patients in whom
(recurrent) syncope was probably caused by beta-blocker
eye drops such as timolol, supporting an advice for re-
consideration of the usefulness and safety of topical beta-
blockers [8, 15, 16]. However, before we stop prescribing
beta-blocker eye drops, more research is needed to
determine whether these glaucoma medications indeed
constitute a higher risk of falling compared to the newer
prostaglandins [17]. Many clinical trials suggest a better
IOP-lowering effect of prostaglandins compared to beta-
blockers; however, some recent (meta-analysis) studies
found a similar effect of the mentioned eye drops [18,
19]. Exclusion of timolol would thus mean the loss of a
very potent and cheap IOP-lowering drug, and an increase
in costs of glaucoma treatment. Therefore we set out to
analyze the possible association between the long-term use
of beta-blocker eye drops, and falls and orthostatic
hypotension in older outpatients of the ophthalmology
outpatient clinic of the Erasmus University Medical Center.
Methods
This cross-sectional study was performed at the outpatient
clinic of the Department of Ophthalmology of the Erasmus
University Medical Center, Rotterdam, the Netherlands.
The Medical Ethics Committee of the Erasmus University
Medical Center approved the study.
Study participants and methods
The inclusion criteria were: age 60 years or older, diagnosis
of ocular hypertension or open-angle glaucoma, use of
topical treatment to lower intraocular pressure for at least
1 year, and most recent visit within the past year. Eligible
topical medication was defined as beta-blockers, prosta-
glandin analogs or combination products with at least one
of the two aforementioned components. Single use of all
other topical medication for lowering intraocular pressure
was excluded, because of the very low numbers of patients
and possible systemic side-effects like dizziness and
systemic hypotension [5, 6].
Subjects fulfilling the inclusion criteria were sent an
information letter by post. One week later, we contacted
them by phone to give further information. If the patient so
wished, an appointment was made for a regular visit to our
outpatient clinic, for an assessment. The assessment
consisted of a structured interview, including questions
regarding frequency and probable causes of falling in the
last 12 months, and an inventory of all current medication.
Physical examination consisted of blood pressure and
pulse rate measurements after 10 minutes in a supine
position. Next, the patient was asked to stand up so we
could measure the blood pressure and pulse rate in an
upright position after 1, 2, 3 and 5 minutes.
Outcome definition
Two separate outcomes were defined, a positive history of
falling, and the presence of orthostatic hypotension respec-
tively. Fall incidents were defined as coming to rest
unintentionally on the ground or a lower level with or
without losing consciousness [20]. A positive falls history
was defined as occurrence of a fall incident within the past
12 months.
Orthostatic hypotension was defined as a decrease of
20 mmHg in systolic and/or 10 mmHg in diastolic blood
pressure on standing [21]. Blood pressure and pulse rate
were measured with a Datascope Accutorr Plus NIBP with
Trend Screen (Datascope Corp., USA). This device has
demonstrated acceptable accuracy and precision for mea-
suring blood pressure [22, 23].
Statistical analysis
We created three groups of patients: a group on eye drops
with beta-blocker (without prostaglandin), a group on
combination therapy (with prostaglandin) and, as the
reference group, the group on prostaglandins. In the
analyses, we combined the beta-blocker and the combina-
tion group as one group of beta-blocker users. Baseline
differences between the subgroups were tested using an
independent t-test and a chi-square test.
We analyzed the association of falling and the use of
beta-blocker eye drops using a binary logistic regression
model, and calculated odds ratios with corresponding 95%
confidence intervals, which can be interpreted as estimators
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of relative risks. The results were adjusted for age, gender
and number of fall-risk-increasing drugs (FRID). FRID
included psychotropic drugs (sedatives, antidepressants,
neuroleptics), cardiovascular drugs [antihypertensives (in-
cluding oral beta-blockers), nitrates, anti-arrhytmics] and
analgesics, hypoglycemics and urinary antispasmodics [14].
For differences in blood pressure and pulse rate between the
mentioned groups we used the Student’s t-test. Analyses were
performed using SPSS (Statistical Package for the Social
Sciences) 15.0.0 (SPSS Inc., Chicago, IL, USA; 2006).
Results
Of the 286 eligible subjects, 148 agreed and were able to
participate in the time-frame of our study (mean age 73.7 years,
range 61–91 years). The other 138 patients could either not be
contacted (N=56), or were unable to participate for several
reasons: too difficult to get to the clinic (N=27), illness (N=
17), poor command of the Dutch language (N=5), unknown
(N=13), other reasons (N=20). The non-responders were on
average 3 years older (p=0.002 adjusted for gender).
The patients’ general characteristics are shown in
Table 1. The mean duration of usage of topical ophthalmic
medication without changes in prescription was 2.87 years
(range 1–13 years). Figure 1 shows the type and percen-
tages of topical medications in our study.
Of the 148 subjects, 41 (27.7%) reported at least one fall
in the past year. Of those, 19 (12.8%) were multiple fallers,
of whom nine used beta-blocker eye drops. Prevalence of
falling was not significantly different between men and
women [odds ratio (OR) for females 1.39; 95% confidence
interval (CI): 0.664–2.909 compared to males; adjusted for
age and number of FRID].
Mean number of prescribed drugs used by subjects,
including injections (insulin, vitamin B-12) and eye drops,
was 5.09 (range 1–16). The risk of a positive falls history did
not increase with the number of different medications used.
Mean number of FRID use was 2.02 (range 0–12).We found a
significant higher risk of falling for the number of FRIDs (OR
1.20; 95% CI: 1.017–1.407 adjusted for age and gender), but
not specifically for the ophthalmic medication under study.
The results on risk of falling and complaints of dizziness
on beta-blocker eye drops are displayed in Table 2. There
were no statistically significant differences between the
groups for falls or dizziness, suggesting that there is no
higher risk of falling or dizziness with long-term use of
topical beta-blockers. As falling seems related to visual
field status, we added visual field data (mean deviation) to
the model, but that did not statistically significantly change
the risk estimate (OR 0.63; 95% CI 0.244–1.605). The risk
of falling increased slightly (OR 0.76; 95% CI 0.329–
1.740) if we combined the oral beta-blockers and eye drops
versus the group without any beta-blocker use (‘clean’
group). This was not the case for the other two outcomes.
Mean blood pressures were similar in the defined
subgroups. The mean systolic and diastolic blood pressure
increased significantly (p<0.001) between 1 and 2 minutes
Table 1 General characteristics of participants (N=148 ophthalmology outpatients)
Prostaglandin Beta-blocker Combination Total P-value**
N % (s.d.) N % (s.d.) N % (s.d.) N %
Responders
N 63 42.6% 36 24.3% 49 33.1% 148 100.0% 0.07
N female 22 34.9% 25 69.4% 26 53.1% 73 49.3% <0.01
Mean age 75.4 (6.79) 72.1 (7.26) 72.5 (6.64) 73.7 (6.98) 0.01
Mean Body Mass Index 25.5 (4.2) 26.2 (3.0) 26.3 (4.1) 25.9 (3.92) 0.22
Mean medication usage* 5.6 (3.8) 4.5 (3.0) 4.9 (2.6) 5.1 (3.3) 0.12
Mean nr. of FRID 2.3 (2.5) 1.7 (1.6) 1.9 (2.1) 2.0 (2.2) 0.20
N using oral beta-blocker 19 27.8% 10 30.2% 12 24.5% 41 27.7% 0.57
N ocular hypertension 28 44.4% 18 50.0% 9 18.4% 55 37.2% 0.11
Visual acuity*** 0.7 (0.3) 0.8 (0.3) 0.7 (0.3) 0.7 (0.3) 0.63
Negative mean deviation*** 6.0 (6.4) 5.3 (6.2) 10.3 (8.0) 7.2 (7.2) 0.13
Non-responders
N 45 32.6% 24 17.4% 69 50.0% 138 100.0% <0.01
N female 29 64.4% 14 58.3% 43 62.3% 86 62.3% 0.72
Mean age 76.0 (8.30) 75.9 (8.48) 77.4 (7.82) 76.7 (8.06) 0.52
FRID = fall-risk-increasing drugs; s.d. = standard deviation; * = including eye drops; ** = p-values for differences between prostaglandin group
and beta-blocker (including combination) group; *** = most severe eye selected
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in upright position. Orthostatic hypotension occurred in 39
subjects (26.4%), of whom 15 cases (23.8%) were in the
prostaglandin group and 24 cases (28.2%) in the beta-
blocker group. We found no significant difference in risk of
orthostatic hypotension for beta-blocker use (OR 1.67; 95%
CI 0.731–3.793). If we subdivided the beta-blocker group
into a beta-blocker [N (%)=12 (33.3%)] and a combination
group [N (%)=12(24.5%)], we found an OR of 2.32 (95%
CI 0.845–6.345) and of 1.34 (95% CI 0.532–3.382)
respectively, compared to the prostaglandin group (both
adjusted for age, gender and number of FRID).
Figure 2 shows that the mean pulse rate in the group on
beta-blocker eye drops was lower than for the combination
group, and both are lower thanmean pulse rate for the subjects
using only prostaglandin eye drops. The pulse rate increased
significantly (p<0.001) in all subgroups in the period after
10 minutes in supine position to 1 minute in upright position.
The increase in the pulse rate at 1 minute of standing was
significantly lower (p<0.05) in the beta-blocker group than
in the prostaglandin group. However, we found no signifi-
cant difference for the other measured time points, neither
for the beta-blocker group nor for the group using
combination drugs compared to the prostaglandin group.
There were eight patients (5.4%) with an irregular pulse rate.
Of those, five (7.9%) used a prostaglandin, one (2.8%) a
beta-blocker and two (4.1%) combination therapy.
Discussion
The results of our study suggest that stable long-term use of
beta-blocker eye drops is not associated with an increased
Fig. 1 Eye drops used,
and their groups, with total
frequencies of population.
(Types of eye drop for lowering
intraocular pressure)
Table 2 History of falling, dizziness and orthostatic hypotension according to use of different topical drugs
N % Crude OR* 95.0% CI* OR** 95.0% CI**
Falling (1 time or more)
Prostaglandin 21 33.3 1.00 1.00
Beta-blocker use 20 23.5 0.55 0.252–1.202 0.60 0.268–1.327
Dizziness
Prostaglandin 16 25.4 1.00 1.00
Beta-blocker use 26 30.6 1.00 0.448–2.208 1.05 0.469–2.369
Orthostatic Hypotension
Prostaglandin 15 23.8 1.00 1.00
Beta-blocker use 24 28.2 1.56 0.697–3.500 1.67 0.731–3.793
* = adjusted for age and gender; ** = adjusted for age, gender and number of fall-risk-increasing drugs; OR = odds ratio; CI = confidence interval
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risk in falling or dizziness in comparison to the use of
prostaglandin eye drops in older patients with ocular
hypertension or glaucoma. This is in contrast with other
studies, possibly because we studied the long-term users of
topical beta-blockers. Furthermore, there may be an
increased risk of orthostatic hypotension, although in our
study this did not reach statistical significance. However,
we did find a significantly lower increase in pulse rate
after 1 minute of standing in topical beta-blocker users,
which, in daily life, may contribute to fall risk on standing
up.
As mentioned earlier, treatment of glaucoma is based on
lowering IOP with topical medication. Timolol was one of
the first topical drugs available for the treatment of elevated
IOP, with only a few ocular side-effects. It revolutionized
the medical therapy of glaucoma at the end of the 1970s.
Now, almost 30 years later, it still remains a frequently
prescribed IOP-lowering drug, even though by now many
systemic (side-)effects have been identified; in the worst
case, an adverse event can lead to death [7, 24]. There are
four types of side-effects of beta-blockers: cardiovascular
(heart failure, arrhythmia, altering serum lipids, decrease in
blood pressure), pulmonary [exacerbation of reactive air-
ways disease (asthma, COPD)], central nervous system
(headaches, weakness, depression) and endocrine (hypo-
glycemia in diabetes) [3, 7, 24–28]. Several studies suggest
that the prevalence of these side-effects is less common in
selective topical beta-blocker (betaxolol) [7, 17, 25, 29], but
the contrary has also been shown [30, 31].
At least 80% of the administered eye drop can be
absorbed into conjunctival, nasal (through the nasolacrimal
duct), oropharyngeal and gastrointestinal mucosa and cause
systemic side-effects [7, 8]. There is no hepatic first-pass
effect, therefore topical administration “mimics” intrave-
nous rather than oral administration. Two drops of a 0.5%
standard dose of timolol in one eye each can approximate to
a 10 mg oral dose to treat systemic hypertension [3, 24, 29].
There is a considerable variation in the degree of
systemic absorption between individuals. Older individuals
have also a slower metabolism of pharmaceuticals and can
thus reach higher plasma levels. However, cardiovascular
side-effects of timolol eye drops have been reported at low
plasma levels (<2.8 ng/ml) [32] and even at undetectable
plasma levels (<1.0 ng/ml) [32, 33]. This is probably due to
the long-lasting occupancy of the beta-receptors by their
antagonists in elderly patients [34].
Pharmacokinetic studies have shown that only 1–7% of
the administered eye drop penetrates the cornea and that
the maximal tear film concentration is achieved with
usage of 20 μl [24]. The remaining amount of the
administered eye drop will simply overflow the eye or
drain into the nasolacrimal duct. With ageing, the flow of
tears will also decrease, which will increase complaints of
irritation, especially when applying the topical medication
[6]. Due to this, the concentration and absorption into the
cornea will decrease through a dilution effect, which will
result in a lower response of eye drops in certain subjects,
which might lead to an increase in the dose. It is also
possible that patients apply their topical medication drop at
more than the one drop prescribed in one or both eyes,
leading to potential overdose and increased risk of systemic
side-effects.
Limitations of the study
One of the limitations of our study is that being a cross-
sectional study, the results depend on the recall of falling,
which might be sensitive to recall bias. It is reported that
13–32% of interviewed subjects do not remember if they
have fallen [35]. This is backed up by the fact that in our
study, the number of patients who actually fell in the past
12 months was very low compared to population studies on
this topic. Another possible limitation concerns the non-
responders, who were older and used slightly more topical
Fig. 2 Mean pulse rates.
(u.p. = upright position)
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beta-blockers, which could lead to selection bias, since the
participants may have constituted a healthier group com-
pared to the non-participants.
Side-effects of beta-blockers usually occur shortly after
the start of use. Because one of our inclusion criteria was a
stable long-term use of IOP-lowering medication over the
last year, this may have led to an under-reporting of side-
effects. Furthermore, confounding by indication might also
play a role: patients with a cardiovascular history are not
likely to receive ophthalmic beta-blockers from their
ophthalmologist.
All the participants were diagnosed with ocular hyperten-
sion or open-angle glaucoma. It is known that one of the
complications of glaucoma is visual field loss, which is also
one of the many risk factors for falling. However, it is
inconclusive whether there is an association between reduced
visual fields and increased fall risk [17].
Finally, the total number of subjects was relatively small,
and therefore the results may not be significantly associated
because of a lack of power (67%). However, the data do not
suggest a large difference between the subgroups.
Considering the extensive use of beta-blockers in
glaucoma patients worldwide, the number of published
case-reports on side-effects is low and mainly focused on
cardiovascular adverse events [8, 15]. This might indicate
that there is a special subgroup of patients who are at
increased risk for these side-effects [e.g., older patients with
incident co-morbidity (infection, CVA, weight loss, cardio-
vascular events, etc.), orthostatic hypotension caused by
autonomic dysfunction and/or co-medication]. The under-
lying mechanism of cardiovascular side-effects is probably
cerebral hypoperfusion, especially a transient global cere-
bral hypoperfusion in syncope [36]. Autonomic failure
increases with age, and is probably an important cause of
orthostatic hypotension in older patients [37, 38].
Pulmonary side-effects are less frequently reported.
Probably patients at risk of these side-effects are more
easily identified anamnestically. Lung complaints often can
even be observed during the ophthalmic examination (e.g.,
dyspnoe, wheezing). The cardiovascular risk profile
includes heart failure, arrhythmias and changes in serum
lipids, which are often not known by the patient himself,
and cannot easily be observed during ophthalmic examina-
tion. To minimize the risk, a complete pre-treatment
cardiovascular examination could be performed; whether
this is cost-effective has not yet been investigated.
In summary, we found no increased risk for falls,
orthostatic hypotension or dizziness in ophthalmic outpatients
on stable long-term use of beta-blocker eye drops. However,
we did find a lower baseline pulse rate in rest (supine) and a
diminished increase in pulse rate at 1 minute of standing in the
subjects on ophthalmic beta-blocker eye-drops, which—in
daily life—may contribute to increased fall risk.
Further research in prospective studies with larger
numbers of participants is needed to verify our findings,
to quantify the incidence of serious adverse events, and to
identify the subgroups at risk, especially those at risk of
cardiovascular side-effects.
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